Abstract: A method for preventing conception in mammals wherein a composition containing (1) free LHRH or its analog and (2) an immunogenic conjugate between LHRH or its analog and a carrier protein is administered to the mammals Free LHRH or its analog acts to prevent conception in the mammal during the period from administration to about 6 weeks; the immunogenic conjugate acts to prevent conception during the period from about 6 weeks after administration until the LHRH antibodies formed in response to the conjugate are metabolized, generally about 0.5-2 years.
Abstract: A composition for the sustained release of a biologically active therapeutic agent wherein the matrix of the sustained release composition is composed of an amorphous carbohydrate glass matrix comprising a suitable carbohydrate and an agent which retards the recrystallization of the carbohydrate and a biologically active therapeutic agent and a water-insoluble wax dispersed throughout the matrix. Biologically active therapeutic agents which can be incorporated into the carbohydrate glass matrix include prolactin, growth hormones, serum albumins, growth factors or any biologically active fragment or recombinant form thereof.
Abstract: A dispensing package assembly useful for dispensing a predetermined amount of a fluent material comprises a relatively stiff base sheet, a blister overlay appended to the overlay and a dispenser pouch housed within the confines of the overlay and the sheet. The blister overlay having a main cavity and a secondary cavity includes a dispenser depression, preferably in the shape of a thumb indention, which protrudes downward into the main cavity. A shearing depression extending laterally through the secondary cavity defines an area of reduced depth within the secondary cavity. The main body of the pouch is located within the overlay main cavity having a dispensing channel or passageway extending therefrom beneath the shearing depression and into the secondary cavity.
Abstract: The present invention relates to compositions for the sustained release of drugs and to methods for the production of such compositions. In one embodiment, somatotropin is layered onto non-pareil seeds, which, in turn are sprayed with a glycine solution. Next, a coating of a wax mixture is applied.
February 10, 1992
Date of Patent:
July 12, 1994
Mallinckrodt Veterinary, Inc.
Siva N. Raman, Matthew W. Gray, Rodger L. Smith
Abstract: Monoclonal antibodies are provided which differentiate between native and modified sequence proteins. Also provided are methods for using monoclonal antibodies to determine the relative amount of native and modified sequence proteins in a sample.
Abstract: A method for producing high purity silica and ammonium fluoride from silicon tetrafluoride-containing gas wherein silicon tetrafluoride-containing gas from the acidulation of phosphorus-containing rock is recovered and the liquid entrainment is separated from the gas. The recovered gas is converted to an ammonium fluosilicate solution and is ammoniated to produce high purity silica and ammonium fluoride. The recovered gas can be converted to an ammonium fluosilicate solution either by absorbing the gas directly in a solution of ammonium fluoride or by first absorbing the gas in water to produce fluosilicic acid and then reacting the fluosilicic acid with ammonia or ammonium fluoride.
Abstract: A method for production of high specific surface area silica gel by hydrolysis of silicon tetrahalide, wherein a solution of silicon tetrahalide in a non-reactive solvent such as alcohol is mixed with water to produce silica gel having a high surface area and narrow pore diameter distribution especially suited for use as normal phase packing material in high performance chromatography columns. The water contains fluoride ions if the halide is chloride. Reverse phase packing material can be prepared by reacting the normal phase silica gel with organochlorosilanes to prepare bonded reverse phase material for use in high performance liquid chromotagraphy systems.
April 24, 1989
Date of Patent:
October 27, 1992
International Minerals & Chemical Corp.
Paul C. Chieng, Deborah J. Brame, Alexander H. T. Chu
Abstract: Human Growth Hormone-Releasing Factor (hGRF) analogs having the sequence [Pro.sup.0, X.sup.15, Y.sup.27 ]-hGRF(1-A)-B, wherein X is selected from the group consisting of Ala and Gly, Y is selected from the group consisting of Ile, Leu, Val, Nle and Met, A has a value from 29-44, and B is NH.sub.2, OH or COOH are synthesized and administered to animals to stimulate the release of Growth Hormone (GH).
Abstract: A strip carriage adapter and corresponding strip cartridge which allows conversion of a handgun-type implanter which uses cylinder-type pellet cartridges to one which uses strip-type pellet cartridges.
Abstract: Porcine somatotropin (pST) and dietary lysine are administered in combination in dosages of from about 1-20 mg/swine/day pST and from about 0.9-1.6% by weight dietary lysine to synergistically promote growth, improve weight gain and increase feed utilization efficiency in swine. Administration of the compounds is conveniently accomplished by (1) administering porcine somatotropin (pST) to swine using conventional methods such as injections or implants and (2) feeding the swine a feed composition containing the lysine.
Abstract: A method for recovering a recombinant protein from a protein solution containing high molecular weight contaminating proteins by directly adding Group IIA metal salts to the solution in amounts sufficient to selectively precipitate the high molecular weight protein contaminants is disclosed.The high molecular weight precipitates are removed and the solution is further processed to remove low molecular weight contaminating proteins and other non-protein contaminants. The recombinant protein is subsequently recovered and further processed to produce a protein composition suitable for its intended use.
Abstract: A high titer fermentation process using transformed Escherichia coli cells carrying a plasmid containing DNA which codes for Somatomedin C is disclosed. Titers of about 900-1000 mg/L have been obtained using the method of the present invention; about two times the titer of prior art processes.
Abstract: A method for recovering a recombinant protein from a protein solution containing high molecular weight containing proteins by directly adding amine or quaternary ammonium compounds to the solution in amounts sufficient to selectively precipitate the high molecular weight protein contaminants.The high molecular weight precipitates are removed and the solution is further processed to remove low molecular weight contaminating proteins and other non-protein contaminants. The recombinant protein is subsequently recovered and further processed to produce a protein composition suitable for its intended use.
Abstract: The present invention provides a stable and bioactive somatotropin which has its small-loop sulfhydryl groups derivatized and a method for producing the small-loop derivatized somatotropin. The small-loop derivatized somatotoropin is stable during long term storage, i.e. it forms very few dimers, oligomers, and aggregates which inactivate the somatotropin, and has a bioactivity equal to or greater than that of the non-derivatized somatotropin.
Abstract: High titers of polyether antibiotics are obtained in a fermentation broth by inoculating a nutrient fermentation broth with a microorganism capable of producing a polyether antibiotic. Growth of the microorganism is established in the broth by incubating the inoculated broth at a physiologically acceptable temperature until pH of the broth begins to rise upon establishment of growth of the microorganism. A free fatty acid then is fed into the broth to achieve and maintain a free fatty acid concentration in the broth of about 0.1% by weight or greater but less than a level at which the free fatty acid is toxic to the microorganism. The free fatty acid is fed into the broth during the remainder of fermentation at about a rate at which the free fatty acid is consumed by the microorganism, to product high titers of the polyether antibiotic.
Abstract: A method for recovering a recombinant protein from a protein solution containing high molecular weight contaminating proteins by directly adding a flocculant to the solution in amounts sufficient to selectively precipitate the high molecular weight protein contaminants is disclosed.The high molecular weight precipitates are removed and the solution is further processed to remove low molecular weight contaminating proteins and other non-protein contaminants. The recombinant protein is subsequently recovered and further processed to produce a protein composition suitable for its intended use.
Abstract: A polyether and antibiotic material is prepared by forming discrete polyether antibiotic-containing agglomerates which are separable from an aqueous medium, by producing a polyether antibiotic through cultivation of a polyether antibiotic-producing microorganism in a generally aqueous nutrient-containing fermentation broth under conditions wherein at the end of fermentation, a lipid is present in the broth in a sufficient amount to form discrete agglomerates with polyether and antibiotic in the fermentation broth, whereupon the applomerates are separated from the broth.
Abstract: An aqueous medium having dispersed therein hydrophobic, polyether antibiotic-containing droplets, is mixed to cause the droplets to collide with each other and coalesce to form agglomerates which are separable from the medium.
Abstract: Human Growth Hormone-Releasing Factor (hGRF) analogs having the sequence [X.sup.3, Y.sup.8, Z.sup.25, Nle.sup.27 ]-hGRF(1-A)--B, wherein X, Y and Z are selected from the group consisting of Asn and Asp, A has a value from 29-44, and B is NH.sub.2 or OH are synthesized and administered to animals to stimulate the release of Growth Hormone (GH).